Cargando…
No Evidence Indicates Famotidine Reduces the Risk of Serious Disease in COVID-19 Patients After Propensity Score Matching: Meta-Analysis and Systematic Reviews
Autores principales: | Li, Weizheng, Dong, Yongxue, Lei, Xianmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409265/ https://www.ncbi.nlm.nih.gov/pubmed/34471967 http://dx.doi.org/10.1007/s10620-021-07214-9 |
Ejemplares similares
-
Famotidine and Coronavirus Disease 2019
por: Freedberg, Daniel E., et al.
Publicado: (2021) -
Famotidine and Mortality in Coronavirus Disease 2019
por: Sethia, Rahul, et al.
Publicado: (2021) -
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study
por: Freedberg, Daniel E., et al.
Publicado: (2020) -
What Underlies the Benefit of Famotidine Formulations Used During COVID-19?
por: Singh, Vijay P., et al.
Publicado: (2021) -
A commentary on ‘Laparoscopic versus open repeat hepatectomy for recurrent hepatocellular carcinoma: a systematic review and meta-analysis of propensity score-matched cohort studies’
por: Zhong, Furui, et al.
Publicado: (2023)